Sangamo’s stock sinks 50% as Pfizer halts haemophilia A gene therapy partnership
Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.
Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.
What's Your Reaction?
